EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic

Fei Zhu, Shiyang Ma, Yizhong Xu, Ziyou Zhou, Peipei Zhang, Wenzhong Peng, Hang Yang, Caixia Tan, Jie Chen, Pinhua Pan

PLOS Neglected Tropical Diseases · 22.01.2025 · 19 (1) · e0012815

DOI: 10.1371/journal.pntd.0012815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 22.01.2025. Verfasst von Fei Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hos…. Hauptthemen laut MEDLINE: Viral Vaccines, Phlebovirus, Pandemics. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key R&D Program of Hunan Province, Natural Science Foundation of ChangSha, Natural Science Foundation of Hunan Province of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a novel identified pathogen, despite two decades of research on SFTSV, the potential widespread threats pose a significant challenge for researchers in developing new treatment and prevention methods. In this present, we have developed a multi-epitope mRNA vaccine for SFTSV and valid it with in silico methods. We screened 9 immunodominant epitopes for cytotoxic T cells (CTL), 7 for helper T cells (HTL), and 8 for Linear B-cell (LBL) based on promising candidate protein Gn, Gc, Np, and NSs. All predicted epitopes demonstrated strong antigenicity without any potential harm to humans. Additionally, the high conservancy is required to cover different strains. All epitopes as well as adjuvants were constructed into a final vaccine, which was further assesd by calculating of physicochemical properties. Then, we docked the vaccine protein with immune receptors and analyzed the complexes with dynamic simulations to evaluate its affinity to receptors. Finally, the vaccine sequence was constructed into a mRNA sequence. The constructed vaccine is a potential candidate for combating SFTSV by stimulating protective humoral and cellular immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Viral VaccinesPhlebovirusPandemicsHumansEpitopes, T-LymphocyteVaccines, SyntheticRNA, MessengerEpitopes, B-LymphocytemRNA VaccinesImmunodominant EpitopesVaccine DevelopmentT-Lymphocytes, CytotoxicAnimals

Substanzen

Viral VaccinesEpitopes, T-LymphocyteVaccines, SyntheticRNA, MessengerEpitopes, B-LymphocytemRNA VaccinesImmunodominant Epitopes

Autor:innen und Institutionen

  • Department of Respiratory Medicine, National Key Clinical Specialty, Branch of National Clinical Research Center for Respiratory Disease, Xiangya Hospital, Central South University, Changsha, China.
  • Center of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, China.
  • Clinical Research Center for Respiratory Diseases in Hunan Province, Changsha, China.
  • Hunan Engineering Research Center for Intelligent Diagnosis and Treatment of Respiratory Disease, Changsha, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China.
  • Department of Infection Control Center, Xiangya Hospital, Central South University, Changsha, China.

Förderung

  • Key R&D Program of Hunan Province
  • Natural Science Foundation of ChangSha
  • Natural Science Foundation of Hunan Province of China
  • The Scientific Research Program of FuRong Laboratory
  • National Natural Science Foundation of China
  • The National Natural Science Foundation of China
  • Project Program of central south university graduate education teaching reform
  • The national key clinical specialist construction programs of China

Zitieren

APA

Zhu, F., Ma, S., Xu, Y., Zhou, Z., Zhang, P., Peng, W., Yang, H., Tan, C., Chen, J., & Pan, P. (2025). Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic. PLOS Neglected Tropical Diseases, 19(1), e0012815. https://doi.org/10.1371/journal.pntd.0012815

Vancouver

Zhu F, Ma S, Xu Y, Zhou Z, Zhang P, Peng W, et al. Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic. PLOS Neglected Tropical Diseases. 2025;19(1):e0012815. doi:10.1371/journal.pntd.0012815

BibTeX
@article{Zhu2025,
  author = {Zhu, Fei and Ma, Shiyang and Xu, Yizhong and Zhou, Ziyou and Zhang, Peipei and Peng, Wenzhong and Yang, Hang and Tan, Caixia and Chen, Jie and Pan, Pinhua},
  title = {Development of a novel multi-epitope mRNA vaccine candidate to combat SFTSV pandemic},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  volume = {19},
  number = {1},
  pages = {e0012815},
  doi = {10.1371/journal.pntd.0012815}
}
Kostenlos starten →